In breast cancer, elevated levels of IL-33 have been correlated with increased proliferation, immunosuppression, and upregulation of CSC markers such as CD44 and ALDH1, primarily through activation of the Wnt/β-catenin signaling pathway [217]. The gene discussed is CD44; the disease is breast carcinoma.